MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2017.1166 MCO-0-0-1166 Articles Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma PanQun-Xiong SuZi-Jian ZhangJian-Hua WangChong-Ren KeShao-Ying Department of Oncological Surgery, Quanzhou First Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China Correspondence to: Dr Qun-Xiong Pan, Department of Oncological Surgery, Quanzhou First Affiliated Hospital of Fujian Medical University, 250 Anji Road, Fengze, Quanzhou, Fujian 362000, P.R. China, E-mail: 710262737@qq.com 04 2017 16 02 2017 6 4 566 574 06052016 26092016 Copyright © 2017, Spandidos Publications 2017

High Glasgow Prognostic Score (GPS) has been associated with poor prognosis in patients with lung, ovarian, colorectal and renal cancer, as well as hepatocellular carcinoma. The aim of this study was to investigate the prognostic value of GPS in patients with intrahepatic cholangiocarcinoma (ICC) undergoing partial hepatectomy. A total of 72 patients with pathologically confirmed ICC were classified according to their GPS scores assigned based on the preoperative levels of C-reactive protein (CRP) and albumin. Their clinicopathological data were retrospectively assessed using univariate and multivariate analysis to determine their association with overall survival and recurrence. High GPS scores in ICC patients were associated with preoperative levels of CRP (P<0.001) and albumin (P<0.001), frequency of ascites accumulation (P=0.035), lymph node metastasis (P=0.002) and tumour size (P=0.005). On univariate analysis, preoperative levels of CRP (P<0.001), albumin (P=0.016) and carbohydrate antigen 19–9 (P=0.038), hepatitis B virus (HBV) positivity (P=0.009), occurrence of lymph node metastasis (P=0.001), Child-Pugh class B (P=0.013) and high tumour-node-metastasis (TNM) stage (P=0.002) were found to be associated with the 1- and 3-year overall survival. Multivariate analysis suggested that GPS score (HR=2.037, 95% CI: 1.092–3.799, P=0.025), TNM classification (HR=2.000, 95% CI: 1.188–3.367, P=0.009) and HBV positivity (HR=0.559 95% CI: 0.328–0.953, P=0.032) were independently associated with patient survival. High GPS scores also predicted ICC recurrence. In conclusion, our results demonstrated that GPS may serve as an independent marker of prognosis in patients with ICC following partial hepatectomy.

 Glasgow Prognostic Score intrahepatic cholangiocarcinoma prognostic marker Introduction

Intrahepatic cholangiocarcinoma (ICC) is an intrahepatic malignancy arising from the biliary epithelium in the intrahepatic bile duct from the segmental and area ducts and their finer branches to the small bile ducts and ductules (1,2). ICC is the second most frequent intrahepatic primary liver tumour after hepatocellular carcinoma (3), accounting for 5–10% of primary liver cancer cases (4). Of note, the global incidence of ICC has been steadily increasing over the last 30 years (4). From the early 1970s to 1999, the ICC incidence in United States and China increased by >150% (4,5). Due to a lack of clinical symptoms and appropriate markers for early diagnosis, ICC is usually diagnosed at an advanced stage (4), mostly with local invasion, liver parenchymal and lymph node metastases, leading to a poor outcome following surgical removal, which is currently the only curative option (6,7). The increasing incidence of ICC, its poor prognosis and lack of treatment options necessitate further studies on its risk factors, early diagnostic markers and prognostic factors.

A number of prognostic factors have previously been reported for ICC, including liver function, vascular invasion, tumour-node-metastasis (TNM) classification and lymph node metastasis (8,9); however, there is little consensus regarding the appropriate prognostic factors and thresholds (10,11). Accumulating evidence indicates the prospective of inflammation-based parameters as prognostic factors (12). This is supported by the wide range of associations between inflammation and tumour initiation, invasion and metastasis (13,14). Tumour infiltration and infiltrating lymphocytes in the tumour microenvironment induce the production of a repertoire of cytokines and inflammatory factors (15); in turn, interleukin (IL)-6, tumour necrosis factor (TNF) and neutrophil accumulation due to the systemic inflammation, enhance tumour growth, invasion and metastasis (16–19). Targeting IL-6 and TNF to interrupt their signalling cascades has been demonstrated to reduce angiogenesis, myeloid cell infiltration and tumour growth (20,21).

Over the past decade, a number of parameters and scoring systems have been developed based on systemic inflammation, which may be evaluated by the serum levels of platelets, neutrophils, lymphocytes, albumin and C-reactive protein (CRP), to assess the prognosis of malignant solid tumours. These include the Glasgow Prognostic Score (GPS), which is based on serum CRP and albumin levels (22–28), neutrophil-to-lymphocyte ratio (NLR) (29,30), platelet-to-lymphocyte ratio (31,32), prognostic nutritional index (33,34), and prognostic index (34,35).

Certain inflammation-based parameters and scoring systems were previously shown to reliably predict the prognosis of cholangiocarcinoma. Preoperative NLR is correlated with the overall survival of ICC patients, and NLR>5 is an independent risk factor for recurrence (36). GPS is an independent prognostic factor for extrahepatic cholangiocarcinoma according to a study on 62 patients (37). The aim of the present study was to investigate the feasibility of using preoperative GPS as an ICC prognostic factor.

 Patients and methods <sec> <title>Patient selection

The ICC subjects were recruited among patients who had undergone partial hepatectomy performed by the same group of surgeons at the Department of Oncological Surgery, Quanzhou First Hospital, Fujian Medical University (Quanzhou, China) from June, 2005 to September, 2011. All selected patients had complete long-term follow-up records and their clinical background information was available for retrospective analysis. Patients with preoperative metastasis, or those undergoing systemic chemotherapy, transcatheter arterial chemoembolization, or local ablation therapy, as well as patients with acute inflammation or rheumatoid arthritis, were excluded. Blood tests were performed 3 days prior to surgery and ICC was confirmed by postoperative histopathological examination.

The present study complied with the standards of the Helsinki Declaration on human research ethics and was approved by the Institutional Ethics Board of Fujian Medical University. Written informed consent from the investigated patients was not obtained due to the retrospective nature of this study. All data were analysed anonymously.

 Follow-up survey and data collection

The follow-up surveys were conducted monthly to quarterly within 2 years after surgery, quarterly to half-yearly between 2 and 5 years, and half-yearly thereafter. The survey included comprehensive medical history, measurement of carbohydrate antigen 19–9 (CA19-9) levels and imaging surveillance by chest radiography, abdominal Doppler ultrasonography and computed tomography. Survival was calculated in months from the date of surgery to death, and disease-free survival as months from the date of surgery to recurrence. Recurrence was defined as any unequivocal occurrence of new cancer foci during imaging surveillance or histopathological analysis. The follow-up was continued for ≤67 months (mean, 24 months), ending on September 1, 2014 for all 72 patients. Following institutional ethics approval, the complete medical files, including images, clinical pathological materials, and follow-up records, were archived in a database for retrospective analysis.

 Clinical data, biochemical parameters and GPS

The size and number of tumours and presence of vascular invasion were assessed based on postoperative pathological outcomes. Serum CRP concentration was measured by a nephelometric immunoassay on a Beckman Coulter immunochemistry system (IMMAGE 800; Beckman Coulter, Inc., Brea, CA, USA). Serum CA19-9 levels were assessed by electro-chemiluminescent microparticle immunoassay (Roche Diagnostics, Shanghai, China), and a level > 37 U/ml was considered to be positive. Biochemical parameters, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB) and albumin, were determined using a Beckman Coulter LX-20 clinical chemistry analyser (Beckman Coulter, Inc.). Hepatitis B virus (HBV) was quantified by chemiluminescence using an Architect i2000SR immunoassay analyser (Abbott Diagnostics, Lake Forest, IL, USA). The tumours were staged according to the 7th edition of TNM system (38) issued by the American Joint Committee on Cancer/International Union Against Cancer, and graded following the Edmondson system (39).

GPS was allocated as previously described, combining preoperative serum CRP and albumin levels. Patients with elevated CRP level (>10 mg/l) and hypoalbuminemia (<35 g/l) were scored as 2, patients with only one of the two biochemical abnormalities were scored as 1, and patients with neither of the two abnormalities were scored as 0 (22,23).

 Statistical analysis

All the statistical tests were performed using IBM SPSS Statistics software v.19.0 (IBM SPSS Inc., Armonk, NY, USA). The χ2 test, Fisher's exact probability test and Student's t-test were used for comparison between groups. The non-parametric Mann-Whitney U test was used when variables in groups were not homogeneous. Prognosis was evaluated by 3- and 5-year overall and disease-free survival after surgery. Kaplan-Meier cumulative survivals were calculated and groups with different GPS scores were compared using the log-rank test. The Cox proportional hazards model was used for multivariate analysis and a threshold α=0.05 was used.

 Results <sec> <title>Patient characteristics

The median age of the 72 patients was 55 years (mean ± standard deviation, 53.26±11.05 years); 29 of the patients were male and 43 female (Table I). A total of 63 and 9 patients were classified as Child-Pugh A and B, respectively; there were no class C patients. A total of 34 (47.2%) patients were positive for antibodies against HBV. The overall 1-, 3- and 5-year postoperative survival was 55.56, 29.20 and 8.33%, respectively, with a median survival of 34 months.

A total of 14 (19.4%) patients exhibited elevated CRP levels (>10 g/l), and 16 (22.2%) patients had hypoalbuminemia (serum albumin <35 g/l). As a result, 49 (68.1%) patients were scored a GPS of 0, 16 (22.2%) patients were scored a GPS of 1 and 7 (9.7%) patients were scored a GPS of 2 (Table II). There was no significant difference between the GPS groups in terms of age (P=0.191), gender (P=0.209), ALT (P=0.105), α-fetoprotein (P=0.588), AST (P=0.204), total bilirubin (P=0.816), HBV positivity (P=0.324), CA-199 (P=0.824), tumour number (P=0.850) and vascular invasion (P=0.234). However, significant differences were found between different GPS groups in the preoperative levels of CRP (P<0.001) and albumin (P<0.001), frequency of ascites accumulation (P=0.035), lymph node metastasis (P=0.002) and tumour size (P=0.005). A higher GPS was also correlated with Child-Pugh class (P=0.003) and TNM stage (P=0.048). Patients with higher GPS score (1 or 2) had higher serum CRP levels, lower albumin levels, and were more likely classified as Child-Pugh class B and higher TNM stage, compared with GPS 0 patients; they also more frequently presented with ascites and lymph node metastasis (Table II).

 GPS predicts overall survival

The 1- and 3-year overall survival rates of ICC patients with a GPS score of 0 (GPS-low) were 69.1 and 40.7%, respectively. The 1- and 3-year overall survival rates of ICC patients with a GPS score of 1 were 31.3 and 6.3%, respectively; for patients with a GPS score of 2, these rates decreased to 28.6 and 0%, respectively. Kaplan-Meier analysis with a log-rank test indicated a significant decrease in the survival rate of patients with higher GPS scores (1 or 2) compared with the GPS-low group (Fig. 1, P<0.001). However, there was no significant difference in survival between patients with a GPS score of 1 and 2 (P=0.428); thus, these two populations were merged into a GPS-high group and compared with the GPS-low patients. The 1- and 3-year overall survival rates of patients from the GPS-high group were 30.4 and 10.4%, respectively, which were significantly lower compared with those of the GPS-low group (Fig. 2, P<0.001).

On univariate analysis to assess the other prognostic factors, preoperative CRP (P<0.001), albumin (P=0.016) and CA19-9 (P=0.038) levels were found to be significantly associated with the 1- and 3-year overall survival. Occurrence of lymph node metastasis (P=0.001), HBV positivity (P=0.009), Child-Pugh class B (P=0.013) and high TNM stage (P=0.002) also predicted poor survival in ICC patients.

Due to the association of GPS with CRP and albumin levels, its correlation with patient survival was assessed in a multivariate analysis using a Cox proportional hazards model. Also included in the multivariate analysis were 5 variables other than CRP and albumin, such as CA19-9, occurrence of lymph node metastasis, positivity for HBV, Child-Pugh class and TNM stage, which were correlated with patient survival based on the univariate analysis (Table III). The multivariate analysis revealed that GPS (HR=2.037, 95% CI: 1.092–3.799, P=0.025), TNM classification (HR=2.000, 95% CI: 1.188–3.367, P=0.009) and HBV positivity (HR=0.559, 95% CI: 0.328–0.953, P=0.032) were independently associated with overall survival (Table III).

 GPS correlates with the recurrence of ICC

Analysis of the time and frequency of ICC recurrence following hepatectomy unveiled a significantly higher recurrence frequency among the GPS-high patients compared with that among the GPS-low patients. The GPS-low patients had a 35.3 and 64.7% risk of developing recurrent disease after 1 and 3 years, respectively, whereas ICC recurred in 78.3% of the GPS-high patients after 1 year and 100% after 3 years, indicating a significantly poorer progression-free survival (Fig. 2, P<0.001). Multivariate analysis suggested that GPS (HR=1.969, 95% CI: 1.014–3.822, P=0.045), TNM classification (HR=2.816, 95% CI: 1.565–5.066, P=0.001) and HBV positivity (HR=0.426, 95% CI: 0.232–0.785, P=0.006) were independent prognostic factors for ICC recurrence (Table III).

 Discussion

An association between inflammation and ICC progression has been established. The risk factors for ICC incidence vary with different geographic regions: In Asia, ICC is mainly due to infection by pathogens including liver flukes and hepatitis B and C viruses; in Western countries, it may be attributed to chronic inflammation, primary sclerosing cholangitis, obesity, hepatolithiasis, bacterial infection and bile stasis-related chronic cholangitis (40). Chronic inflammation and biliary irritation are, however, commonly shared among these diseases (40). These support recent findings that inflammation-based scores or parameters may be used as prognostic markers for patients with cholangiocarcinoma (36,37). In this study, we demonstrated that the inflammation-based prognostic score, GPS, is associated with the recurrence and overall survival of ICC patients and may be used as an independent prognostic marker.

Analysis of clinicopathological data of 72 ICC patients indicated that GPS classification precisely reflects the preoperative CRP and albumin levels, Child-Pugh class, tumour size, TNM classification, and the occurrence of ascites and lymph node metastasis. Patients with high GPS scores (1 or 2) exhibited a significantly shorter overall survival compared with those with a low GPS score (0), although no statistically significant difference was observed between patients with GPS scores of 1 and 2, which is likely due to the limited number of patients in these two groups. Our analysis using the Cox hazards model suggested that GPS, as well as TNM classification and HBV positivity, is an independent prognostic factor for the recurrence of ICC and the overall patient survival.

Although GPS has frequently been associated with the prognosis of solid tumours, such as lung (22,23), liver (27,28), kidney (26), ovarian (24), colorectal (25), gastric (41,42) and pancreatic cancer (43), the association has yet to be fully elucidated. One component of the GPS score, CRP, is an acute phase protein synthesized by hepatocytes in response to inflammation, infection, tissue damage and cancer, reflecting systemic inflammation (44). Although there is no causal association between elevated CRP and cancer development, the cytokines that mediate CRP, such as IL-1, IL-6 and TNF, are key pro-inflammatory factors in hepatobiliary inflammation and cancer (45). For example, IL-6 contributes to the growth of malignant cholangiocytes by affecting the promoter methylation and expression of several genes, including epidermal growth factor receptor (46). IL-6 also promotes malignant cholangiocyte growth by activating the mitogen-activated protein kinase pathway and enhancing the expression of the anti-apoptotic protein myeloid cell leukemia-1 in an either autocrine or paracrine manner (47,48). These are consistent with the significant preoperative increase of IL-6 in the serum of patients with cholangiocarcinoma and its apparent decrease after surgery (49,50). IL-1 family cytokines and TNF also facilitate oncogenesis of cholangiocarcinoma, as previously described (51–53). These may partially underlie the mechanism through which GPS score correlates with the prognosis of ICC patients.

Preoperative serum albumin reflects nutritional status (54,55); it decreases in response to systemic inflammation during malignant tumour growth, leading to hypoalbuminemia and weight loss (56), which may in turn affect the immune system of the cancer patients (57). Hypoalbuminemia therefore suggests systemic inflammation and immune suppression, in association with the initiation and progression of malignant tumours, and has been reported as an independent prognostic marker for ICC (58). These findings explain the correlation of GPS with recurrence and prognosis of ICC patients observed in this study.

Our data indicated that 47.2% of ICC patients were positive for hepatitis B surface antigen, and these patients generally exhibited longer overall and progression-free survival. Accumulating evidence suggests a correlation of ICC development with HBV infection (59,60). HBV DNA may be detectable in tumour tissues from a proportion of the ICC patients (61,62). Chronic HBV and hepatitis C virus infection represent risk factors for ICC occurrence based on a meta-analysis of 13 case-control and 3 cohort studies (63). However, ICC patients carrying HBV had a better prognosis compared with those without HBV infection (64,65). This is likely due to a lower tendency for metastasis towards the perihepatic lymph nodes and a higher rate of encapsulation in ICC patients with HBV (66,67). In addition, the immunological memory caused by a previous HBV infection may be quickly activated by the HBV-relevant ICC, promoting antitumour immunity (68,69).

The prognosis of ICC is currently assessed postoperatively by the complicated TNM classification, the Barcelona Clinic Liver Cancer staging system (70), and the Cancer Liver Italian Program scoring system (71). GPS scoring represents a simple and easily applicable method, based on preoperative serum CRP and albumin levels, which may be determined biochemically. The present study revealed a significant correlation between the overall and progression-free survival of ICC patients following resection and their preoperative GPS scores, and supports GPS as an effective and easily achievable prognostic marker for ICC patients.

 Acknowledgements

We would like to thank all the members of the Department of Oncological Surgery of the First Affiliated Hospital of Fujian Medical University for their help and support.

 References GuestRVBoulterLKendallTJMinnis-LyonsSEWalkerRWigmoreSJSansomOJForbesSJCell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinomaCancer Res7410051010201410.1158/0008-5472.CAN-13-191124310400 NakanumaYSripaBBatanasaptVLeongASYPonchonTIshakKGIntrahepatic cholangiocarcinoma. Pathology and Genetics of Tumours of the Digestive SystemWorld Health Organization of TumoursHamiltonSRAaltonenLAIARCLyon1731802000 FargesOFuksDLe TreutYPAJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma:by the AFC-IHCC-2009 study groupCancer11721702177201110.1002/cncr.2571221523730 ZouSLiJZhouHFrechCJiangXChuJSZhaoXLiYLiQWangHMutational landscape of intrahepatic cholangiocarcinomaNat Commun55696201410.1038/ncomms669625526346 WangJDQuanZWThe molecular mechanism of cholangiocarcinomaJ Pract Oncol Chin2296982007 de JongMCNathanHSotiropoulosGCPaulAAlexandrescuSMarquesHPulitanoCBarrosoEClaryBMAldrighettiLIntrahepatic cholangiocarcinoma: An international multi-institutional analysis of prognostic factors and lymph node assessmentJ Clin Oncol2931403145201110.1200/JCO.2011.35.651921730269 de GroenPCGoresGJLaRussoNFGundersonLLNagorneyDMBiliary tract cancersN Engl J Med34113681378199910.1056/NEJM19991028341180710536130 LiTQinLXZhouJSunHCQiuSJYeQHWangLTangZYFanJStaging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resectionLiver Int34953960201410.1111/liv.1236424134199 LiHWuJSWangXTLvPGongLSLiuGTianBNLiYYJiangBFactors predicting surgical resection in patients with intrahepatic cholangiocarcinoma and cirrhosisJ Invest Surg27219225201410.3109/08941939.2014.88013824476002 WangYLiJXiaYGongRWangKYanZWanXLiuGWuDShiLPrognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomyJ Clin Oncol3111881195201310.1200/JCO.2012.41.598423358969 PaikKYJungJCHeoJSChoiSHChoiDWKimYIWhat prognostic factors are important for resected intrahepatic cholangiocarcinoma?J Gastroenterol Hepatol23766770200810.1111/j.1440-1746.2007.05040.x17868336 KinoshitaAOnodaHImaiNIwakuAOishiMTanakaKFushiyaNKoikeKNishinoHMatsushimaMThe Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinomaBMC Cancer1352201310.1186/1471-2407-13-5223374755 RoxburghCSMcMillanDCRole of systemic inflammatory response in predicting survival in patients with primary operable cancerFuture Oncol6149163201010.2217/fon.09.13620021215 ArgilésJMBusquetsSToledoMLópez-SorianoFJThe role of cytokines in cancer cachexiaCurr Opin Support Palliat Care3263268200910.1097/SPC.0b013e3283311d0919713854 BalkwillFMantovaniAInflammation and cancer: Back to Virchow?Lancet357539545200110.1016/S0140-6736(00)04046-011229684 KusumantoYHDamWAHospersGAMeijerCMulderNHPlatelets and granulocytes in particular the neutrophils from important compartments for circulating vascular endothelial growth factorAngiogenesis6283287200310.1023/B:AGEN.0000029415.62384.ba15166496 UlichTRDel CastilloJGuoKZIn vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCsBlood7310811019892783370 PhilipMRowleyDASchreiberHInflammation as a tumor promoter in cancer inductionSemin Cancer Biol14433439200410.1016/j.semcancer.2004.06.00615489136 HeikkiläKKEbrahimSLawlorDAA systematic review of the association between circulating concentrations of C reactive protein and cancerEpidemiol Community Health61824833200710.1136/jech.2006.051292 KulbeHChakravartyPLeinsterDACharlesKAKwongJThompsonRGA dynamic inflammatory cytokine network in the human ovarian cancer microenvironmentCancer Res726675201210.1158/0008-5472.CAN-11-217822065722 CowardJKulbeHChakravartyPLeaderDVassilevaVLeinsterDAThompsonRSchioppaTNemethJVermeulenJInterleukin-6 as a therapeutic target in human ovarian cancerClin Cancer Res1760836096201110.1158/1078-0432.CCR-11-094521795409 TomitaMAyabeTChosaENakamuraKPrognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancerAnticancer Res3431373140201424922684 JiangAGChenHLLuHYComparison of Glasgow prognostic score and prognostic index in patients with advanced non-small cell lung cancerJ Cancer Res Clin Oncol141563568201510.1007/s00432-014-1839-425257958 SharmaRHookJKumarMGabraHEvaluation of an inflammation-based prognostic score in patients with advanced ovarian cancerEur J Cancer44251256200810.1016/j.ejca.2007.11.01118155897 IkeguchiMUrushibaraSShimodaRYamamotoMMaetaYAshidaKInflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancerWorld J Surg Oncol12210201410.1186/1477-7819-12-21025022764 RamseySLambGWAitchisonMGrahamJMcMillanDCEvaluation of an inflammation-based prognostic score in patients with metastatic renal cancerCancer109205212200710.1002/cncr.2240017149754 PanQXZhangJHSuZJWangCRKeSYThe Glasgow Prognostic Score is an independent prognostic predictor of hepatocellular carcinoma following radical resectionOncol Res Treat37192197201410.1159/00036108224732643 IshizukaMKubotaKKitaJShimodaMKatoMSawadaTImpact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: A retrospective study of 398 Japanese patientsAm J Surg203101106201210.1016/j.amjsurg.2010.09.03021429472 KanekoMNozawaHSasakiKHongoKHiyoshiMTadaNMuronoKNireiTKawaiKSunamiEElevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapyOncology82261268201210.1159/00033722822538399 OhBSJangJWKwonJHYouCRChungKWKayCSJungHSLeeSPrognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinomaBMC Cancer1378201310.1186/1471-2407-13-7823409924 KwonHCKimSHOhSYLeeSLeeJHChoiHJParkKJRohMSKimSGKimHJClinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancerBiomarkers17216222201210.3109/1354750X.2012.65670522424597 SmithRABosonnetLRaratyMSuttonRNeoptolemosJPCampbellFGhanehPPreoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinomaAm J Surg197466472200910.1016/j.amjsurg.2007.12.05718639229 KasymjanovaGMacDonaldNAgulnikJSCohenVPepeCKreismanHSharmaRSmallDThe predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancerCurr Oncol175258201010.3747/co.v17i4.56720697515 ProctorMJMorrisonDSTalwarDBalmerSMFletcherCDO'ReillyDSFoulisAKHorganPGMcMillanDCA comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome StudyEur J Cancer4726332641201110.1016/j.ejca.2011.03.02821724383 PinatoDJNorthBVSharmaRA novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI)Br J Cancer10614391445201210.1038/bjc.2012.9222433965 GomezDMorris-StiffGToogoodGJLodgeJPPrasadKRImpact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinomaJ Surg Oncol97513518200810.1002/jso.2100118335453 OshiroYSasakiRFukunagaKKondoTOdaTTakahashiHOhkohchiNInflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinomaJ Hepatobiliary Pancreat Sci20389395201310.1007/s00534-012-0550-623138964 HiraokaAKawamuraTAibikiTOkudairaTToshimoriAYamagoHNakaharaHSugaYAzemotoNMiyataHPrognosis and therapy for ruptured hepatocellular carcinoma: Problems with staging and treatment strategyEur J Radiol84366371201510.1016/j.ejrad.2014.11.03825554005 EdmondsonHASteinerPEPrimary carcinoma of the liver: A study of 100 cases among 48,900 necropsiesCancer7462503195410.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E13160935 Leyva-IlladesDMcMillinMQuinnMDemorrowSCholangiocarcinoma pathogenesis: Role of the tumor microenvironmentTransl Gastrointest Cancer17180201223002431 DuttaSCrumleyABFullartonGMHorganPGMcMillanDCComparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancerAm J Surg204294299201210.1016/j.amjsurg.2011.10.01522444831 WangDSRenCQiuMZLuoHYWangZQZhangDSWangFHLiYHXuRHComparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancerTumour Biol33749756201210.1007/s13277-011-0285-z22198641 GlenPJamiesonNBMcMillanDCCarterRImrieCWMcKayCJEvaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancerPancreatology6450453200610.1159/00009456216847382 AllinKHNordestgaardBGElevated C-reactive protein in the diagnosis, prognosis, and cause of cancerCrit Rev Clin Lab Sci48155170201110.3109/10408363.2011.59983122035340 JohnsonCHanYHughartNMcCarraJAlpiniGMengFInterleukin-6 and its receptor, key players in hepatobiliary inflammation and cancerTransl Gastrointest Cancer15870201222724089 WehbeHHensonRMengFMize-BergeJPatelTInterleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expressionCancer Res661051710524200610.1158/0008-5472.CAN-06-213017079474 ParkJTadlockLGoresGJPatelTInhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell lineHepatology3011281133199910.1002/hep.51030052210534331 MengFYamagiwaYUenoYPatelTOver-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytesJ Hepatol4410551065200610.1016/j.jhep.2005.10.03016469407 HeimbachJKGoresGJHaddockMGAlbertsSRNybergSLIshitaniMBRosenCBLiver transplantation for unresectable perihilar cholangiocarcinomaSemin Liver Dis24201207200410.1055/s-2004-82889615192792 JarnaginWRFongYDeMatteoRPGonenMBurkeECBSJ BodniewiczBAM YoussefKlimstraDBlumgartLHStaging, resectability, and outcome in 225 patients with hilar cholangiocarcinomaAnn Surg234507517, discussion 517–519200110.1097/00000658-200110000-0001011573044 YamadaDRizviSRazumilavaNBronkSFDavilaJIChampionMDBoradMJBezerraJAChenXGoresGJIL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanismHepatology6116271642201510.1002/hep.2768725580681 JaiswalMLaRussoNFBurgartLJGoresGJInflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanismCancer Res60184190200010646872 MaemuraKNatsugoeSTakaoSMolecular mechanism of cholangiocarcinoma carcinogenesisJ Hepatobiliary Pancreat Sci21754760201410.1002/jhbp.12624895231 GuptaDLisCGPretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literatureNutr J969201010.1186/1475-2891-9-6921176210 LienYCHsiehCCWuYCHsuHSHsuWHWangLSHuangMHHuangBSPreoperative serum albumin level is a prognostic indicator for adenocarcinoma of the gastric cardiaJ Gastrointest Surg810411048200410.1016/j.gassur.2004.09.03315585392 McMillanDCWatsonWSOO'GormanPPrestonTScottHRMcArdleCSAlbumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight lossNutr Cancer39210213200110.1207/S15327914nc392_811759282 OhkiSShibataMGondaKMachidaTShimuraTNakamuraIOhtakeTKoyamaYSuzukiSOhtoHCirculating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancerOncol Rep28453458201222614133 NakeebAPittHASohnTAColemanJAbramsRAPiantadosiSHrubanRHLillemoeKDYeoCJCameronJLCholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumorsAnn Surg224463473, discussion 473–475199610.1097/00000658-199610000-000058857851 TanakaMTanakaHTsukumaHIokaAOshimaANakaharaTRisk factors for intrahepatic cholangiocarcinoma: A possible role of hepatitis B virusJ Viral Hepat17742748201010.1111/j.1365-2893.2009.01243.x20002305 DonatoFGelattiUTaggerAFavretMRiberoMLCalleaFMartelliCSavioATrevisiPNardiGIntrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: A case-control study in ItalyCancer Causes Control12959964200110.1023/A:101374722857211808716 WuYWangTYeSZhaoRBaiXWuYAbeKJinXDetection of hepatitis B virus DNA in paraffin-embedded intrahepatic and extrahepatic cholangiocarcinoma tissue in the northern Chinese populationHum Pathol435661201210.1016/j.humpath.2011.04.00421777950 PerumalVWangJThuluvathPChotiMTorbensonMHepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United StatesHum Pathol3712111216200610.1016/j.humpath.2006.04.01216938527 ZhouYZhaoYLiBHuangJWuLXuDYangJHeJHepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: Evidence from a meta-analysisBMC Cancer12289201210.1186/1471-2407-12-28922799744 ZhouHBWangHLiYQLiSXWangHZhouDXTuQQWangQZouSSWuMCHepatitis B virus infection: A favorable prognostic factor for intrahepatic cholangiocarcinoma after resectionWorld J Gastroenterol1712921303201110.3748/wjg.v17.i10.129221455328 ZhangLCaiJQZhaoJJBiXYTanXGYanTLiCZhaoPImpact of hepatitis B virus infection on outcome following resection for intrahepatic cholangiocarcinomaJ Surg Oncol101233238201010.1002/jso.2148820169539 PengNFLiLQQinXGuoYPengTXiaoKYChenXGYangYFSuZXChenBEvaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: A possible role of hepatitis B virusAnn Surg Oncol1812581266201110.1245/s10434-010-1458-521207172 ZhouHWangHZhouDWangHWangQZouSTuQWuMHuHHepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesisEur J Cancer4610561061201010.1016/j.ejca.2010.02.00520202823 LlovetJMBrúCBruixJPrognosis of hepatocellular carcinoma: The BCLC staging classificationSemin Liver Dis19329338199910.1055/s-2007-100712210518312 DingFXWangFLuYMLiKWangKHHeXWSunSHMultiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinomaHepatology4914921502200910.1002/hep.2281619206147 WardSMPhaloraPBradshawDLeyendeckersHKlenermanPDirect ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virusJ Infect Dis198813817200810.1086/59109418662131 No authors listed: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigatorsHepatology28751755199810.1002/hep.5102803229731568

Kaplan-Meier analysis of overall survival of intrahepatic cholangiocarcinoma patients. The cases were assigned to Glasgow Prognostic Score (GPS) 0, 1 and 2 groups. There was a significant decrease in the survival rate of patients with higher GPS scores (1 or 2) compared with the GPS-low (0) group (P<0.001). However, no significant difference in survival was observed between patients with a GPS score of 1 and 2 (P=0.428).

Kaplan-Meier survival curves showing the differences in (A) survival and (B) recurrence between the two Glasgow Prognostic Score (GPS) groups (0 vs.1 or 2) in patients with intrahepatic cholangiocarcinoma (ICC). (A) The 1- and 3-year overall survival rates of patients in the GPS-high group were 30.4 and 10.4%, respectively, which were significantly lower compared with the GPS-low group. (B) The GPS-low patients had a 35.3 and 64.7% risk of developing recurrent disease after 1 and 3 years, respectively, whereas ICC recurred in 78.3% of the GPS-high patients after 1 year and 100% after 3 years, indicating a significantly poorer progression-free survival.

Clinicopathological characteristics of the patients.

Characteristics No. Percentage
Gender
  Male 29 40.30
  Female 43 59.70
Age (years)
  Median 55
  Mean ± SD 53.26±11.05
Child-Pugh class
  A 63 87.50
  B   9 12.50
CRP (mg/l)
  ≤10 58 80.60
  >10 14 19.40
Albumin (g/l)
  <35 16 22.20
  ≥35 56 77.80
HBV status
  Positive 34 47.20
  Negative 38 52.80
Vascular invasion
  Yes 40 44.40
  No 32 55.60
Nο. of tumours
  1 55 76.40
  ≥2 17 23.60
Tumour size (cm)
  ≤5 52 72.20
  >5 20 27.80
AFP (ng/ml)
  <400 42 58.30
  ≥400 30 41.70
ALT (U/l)
  ≤40 40 55.60
  >40 32 44.40
AST (U/l)
  ≤40 39 54.20
  >40 33 45.80
Total bilirubin (µmol/l)
  ≤17.1 41 56.90
  >17.1 31 43.10
Ascites
  Negative 63 87.50
  Positive   9 12.50
CA19-9 (U/l)
  <37 27 37.50
  ≥37 45 62.50
Lymph node metastases
  Yes 21 29.20
  No 51 70.80
TNM classification
  I 45 62.50
  II 24 33.33
  III   3 4.20
GPS score
  0 49 68.10
  1 16 22.20
  2   7 9.70

CRP, C-reactive protein; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CA19-9, carbohydrate antigen 19–9; TNM, tumour-node-metastasis; GPS, Glasgow Prognostic Score.

Association of GPS score with clinicopathological characteristics in patients undergoing hepatectomy.

Characteristics Overall (n=72) GPS=0 (n=49) GPS=1 (n=16) GPS=2 (n=7) P-value
Age (years)
  Mean ± SD 53.26±11.05 53.51±11.16 49.88±13.00 59.29±8.538 0.191
Gender 0.209
  Male 29 18   6 5
  Female 43 31 10 2
Child-Pugh class 0.003
  A 63 47 12 4
  B   9   2   4 3
CRP (mg/l) 8.321±16.33 2.34±2.52 12.07±10.24 41.65±34.88 <0.001
Albumin (g/l) 36.99±5.05 39.34±3.12 32.93±5.31 29.90±2.61 <0.001
HBV status
  Positive 34 26   6 2 0.324
  Negative 38 23 10 5
Vascular invasion   0.234
  Yes 40 26   8 6
  No 32 23   8 1
Tumour size (cm) 0.005
  Mean ± SD 5.82±3.42 5.01±3.22 7.06±3.37 8.71±2.81
No. of tumours 0.850
  1 55 37 13 5
  ≥2 17 12   3 2
AFP (ng/ml)
  Mean ± SD 4,130.0±10,926.52 4,645.83±12,107.70 3,088.98±7,596.47 253.63±5,536.98 0.588
ALT (U/l)
  Mean ± SD 83.24±166.23 60.12±73.20 160.81±323.78 67.71±39.13 0.105
AST (U/l)
  Mean ± SD 85.26±153.28 63.40±74.93 140.48±295.08 106.67±51.43 0.204
Total bilirubin (µmol/l)
  Mean ± SD 24.58±26.41 23.96±20.62 28.89±46.83 21.92±15.63 0.816
CA 19–9 (U/l) 0.824
  <37 27 19   5 3
  ≥37 45 30 11 4
Ascites 0.035
  Negative 63 44 15 4
  Positive   9   5   1 4
Lymph node metastases 0.002
  Yes 21 8   9 4
  No 51 41   7 3
TNM classification 0.048
  I   3   3   0 0
  II 24 21   3 0
  III 45 25 13 7

Bold print indicates statistical significance. CRP, C-reactive protein; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CA 19–9, carbohydrate antigen 19–9; TNM, tumour-node-metastasis; GPS, Glasgow Prognostic Score.

Univariate and multivariate analyses of clinicopathological factors for overall and disease-free survival.

Overall survival Disease-free survival
Survival rate (%) Univariate Multivariate Survival rate (%) Univariate Multivariate
Variables 1-year 3-year P value HR (95% CI) 1-year 3-year P value HR (95% CI)
Gender
  Male (n=43) 57.7 35.6   0.137 47.5 16.1   0.120
  Female (n=29) 55.1 23.7 50.6 30.1
Age (years)
  <55 (n=36) 50.0 26.8 0.293 38.9 18.5   0.318
  ≥55 (n=36) 60.4 36.3 54.8 24.7
Child-Pugh class
  A (n=63) 60.1   33.7 0.013 52.0 28.4   0.005
  B (n=9) 22.2 0 15.3 0
CRP (mg/l)
  ≤10 (n=58) 65.2 36.9   <0.001 57.8 32.7 <0.001
  >10 (n=14) 14.3 7.1 7.1 0
Albumin (g/l)
  <35 (n=16) 37.5 7.8 0.016 25.0 0 0.007
  ≥35 (n=56) 62.3 37.3 58.4 31.2
HBV status   0.032 0.006
  Positive (n=34) 67.6 47.2 0.009 (0.328–0.953) 61.8 31.8 0.003 (0.232–0.785)
  Negative (n=38) 43.8 18.4 31.9 10.2
Vascular invasion
  Yes (n=40) 54.3 30.6 0.879    46.4 27.0 0.875
  No (n=32) 53.1 31.3 50.0 21.9
No. of tumours
  1 (n=55) 54.2 31.5 0.838 42.1 25.2   0.820
  ≥2 (n=17) 52.9 29.4 47.1 212
Lymph node metastasis
  Negative (n=51) 62.3 38.1   0.001 60.3 35.6   0.002
  Positive (n=21) 38.1 14.3 28.6 0
Tumour size (cm)
  ≤5 (n=20) 69.6 44.7 0.054 69.1 43.0 0.028
  >5 (n=52) 49.5 29.8 43.8 17.7   
AFP (ng/ml)
  <400 (n=43) 62.1 39.2 0.082 61.0 29.4 0.076
  ≥400 (n=29) 41.4 22.6 36.7 17.6
ALT (U/l)
  ≤40 (n=40) 59.7 31.9 0.622 54.5 19.8 0.798
  >40 (n=32) 52.9 33.1 46.2 26.0
AST (U/l)
  ≤40 (n=39) 66.3 41.1 0.217 61.0 25.7 0.166
  >40 (n=33) 45.5 22.6 38.8 19.8
Total bilirubin (µmol/l)
  ≤17.1 (n=41) 58.3 41.5   0.574 55.4 26.7 0.716
  >17.1 (n=31) 54.8 21.8 45.2 18.1
CA19-9 (U/l)
  <37 (n=27) 66.0 38.8 0.038 62.0 32.5 0.046
  ≥37 (n=45) 46.6 24.0 44.1 16.0
Ascites
  Negative (n=63) 56.9 33.6 0.676 50.4 24.7 0.597
  Positive (n=9) 53.3 20.0 40.0 15.2
TNM classification
  I (n=3) 100 100 0.002 0.009 (1.188 3.367) 100 100 <0.001 0.001 (1.565–5.066)
  II (n=24) 70.1 48.8 65.2 34.5
  III (n=45) 44.4 20.0 37.8 11.1
GPS   0.025 0.045
  0 (n=49) 69.1 40.7 <0.001 (1.092–3.799) 64.7 35.7 <0.001 (1.014–3.822)
  1 or 2 (n=23) 30.4 10.4 21.7 0

Bold print indicates statistical significance. CI, confidence Interval; CRP, C-reactive protein; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CA19-9, carbohydrate antigen 19–9; TNM, tumour-node-metastasis; GPS, Glasgow Prognostic Score.